Alteogen Receives 400,000 Won Target Price on SC Conversion Technology Demand
IBK Securities issued a 'buy' investment rating and a target price of 400,000 won for Alteogen on the 21st, citing expected benefits from global pharmaceutical companies' conversion to subcutaneous injection (SC) formulations. Analyst Jeong Yi-su of IBK Securities explained that demand for SC conver
LucasBennett·09-20 22:45
